← Eichor
Condition: Microsatellite Stable Rectal Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Microsatellite Stable Rectal Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Ca
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06864013Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer
Phase 2 · 1 location(s) · Jinhua Central Hospital · NCT06204094Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
Phase 1/Phase 2 · 1 location(s) · Dan Feng · NCT07281716SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06850103Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS
Phase 2 · 1 location(s) · Fudan University · NCT06218810CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
Phase 2 · 1 location(s) · Fudan University · NCT06281405SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer
Phase 2 · 1 location(s) · Ruijin Hospital · NCT05576480Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tip
Phase 2 · 2 location(s) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRS · NCT06522919Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
Phase 2 · 1 location(s) · Fudan University · NCT05771181FOG-001 in Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 33 location(s) · Parabilis Medicines, Inc. · NCT05919264A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06843434Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advance
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07594925Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Phase 1/Phase 2 · 23 location(s) · National Cancer Institute (NCI) · NCT05691491CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advance
Phase 2 · 1 location(s) · Shanghai Changzheng Hospital · NCT05585814A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants Wi
Phase 1 · 11 location(s) · IDEAYA Biosciences · NCT07540572Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT07528209Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metas
Phase 1 · 8 location(s) · National Cancer Institute (NCI) · NCT06654037A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in
Phase 1 · 10 location(s) · Cartography Biosciences · NCT07321106Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer
Phase 2 · 1 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT05136326Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MS
Phase 2 · 1 location(s) · Fudan University · NCT07150949
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.